drugset / Trial / NCT05848258

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

NCT05848258

RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).

Timeline

Start
2023-05-23
Primary completion
2025-12-08
Completion
2026-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject OCADUSERTIB Small molecule Oral

Indications